Cargando…

The Italian Questionnaire for Cancer Breakthrough Pain Diagnosis, a Multicenter Validation Study

INTRODUCTION: The literature lacks formally validated and reliable tools for the diagnosis of breakthrough cancer pain (BTcP). The Italian Questionnaire for BTcP diagnosis (IQ-BTP) is an 11-item questionnaire aimed at detecting potential-BTP and classifying it into three likelihood classes: high, in...

Descripción completa

Detalles Bibliográficos
Autores principales: Samolsky Dekel, Boaz Gedaliahu, Gori, Alberto, Gunnellini, Marco, Gioia, Angela, Di Marco, Mariacristina, Casale, Giuseppe, Bevilacqua, Marzio, Bersani, Pietro, Melotti, Rita Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8586321/
https://www.ncbi.nlm.nih.gov/pubmed/34091817
http://dx.doi.org/10.1007/s40122-021-00274-9
_version_ 1784597866816208896
author Samolsky Dekel, Boaz Gedaliahu
Gori, Alberto
Gunnellini, Marco
Gioia, Angela
Di Marco, Mariacristina
Casale, Giuseppe
Bevilacqua, Marzio
Bersani, Pietro
Melotti, Rita Maria
author_facet Samolsky Dekel, Boaz Gedaliahu
Gori, Alberto
Gunnellini, Marco
Gioia, Angela
Di Marco, Mariacristina
Casale, Giuseppe
Bevilacqua, Marzio
Bersani, Pietro
Melotti, Rita Maria
author_sort Samolsky Dekel, Boaz Gedaliahu
collection PubMed
description INTRODUCTION: The literature lacks formally validated and reliable tools for the diagnosis of breakthrough cancer pain (BTcP). The Italian Questionnaire for BTcP diagnosis (IQ-BTP) is an 11-item questionnaire aimed at detecting potential-BTP and classifying it into three likelihood classes: high, intermediate, and low. METHODS: A multicenter, prospective, and observational study was designed to validate the IQ-BTP. In three consecutive visits with each cancer patient, the demographic and clinical details of the patient, the Brief Pain Inventory (BPI) scores, IQ-BTP outcomes, and clinicians' autonomous BTcP diagnosis (gold standard) and the agreement of this diagnosis with IQ-BTP outcomes were recorded. The assessed domains for IQ-BTP validation were: Validity, including content and face validity, construct validity (hypothesis testing, and cross‐cultural validity\measurement invariance), and criterion validity; Reliability (internal consistency, reliability, and measurement error); Interpretability, and Responsiveness. RESULTS: Seven palliative and pain management facilities in Italy recruited 280 patients, yielding 753 evaluations. Using the IQ-BTP, the rate of potential-BTcP was 27.2%, of which its likely presence was high in 52.7% of patients, intermediate in 38.5, and low in 8.8%. The BPI item scores differed significantly between the two IQ-BTP classes (no-BTcP and potential-BTcP classes). The correlation of the latter class with BPI items was significant but low. The IQ-BTcP showed two principal components, accounting for 66.6% of the variance. Cronbach’s α was 0.71. The agreement rate between the gold standard and IQ-BTP outcomes was 82%. Cohen's [Formula: see text] was 0.535. The IQ-BTP showed sensitivity and specificity of 69 and 86%, respectively. CONCLUSIONS: The IQ-BTP extensive formal validation showed satisfactory psychometric and validity properties. Its content, face, construct, and criterion validities and its reliability, interpretability, and responsiveness were shown. Its use enabled potential-BTcP to be identified and differentiated into three likelihood classes with direct therapeutic and epidemiological implications. The latter may be confirmed in future studies. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40122-021-00274-9.
format Online
Article
Text
id pubmed-8586321
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-85863212021-11-23 The Italian Questionnaire for Cancer Breakthrough Pain Diagnosis, a Multicenter Validation Study Samolsky Dekel, Boaz Gedaliahu Gori, Alberto Gunnellini, Marco Gioia, Angela Di Marco, Mariacristina Casale, Giuseppe Bevilacqua, Marzio Bersani, Pietro Melotti, Rita Maria Pain Ther Original Research INTRODUCTION: The literature lacks formally validated and reliable tools for the diagnosis of breakthrough cancer pain (BTcP). The Italian Questionnaire for BTcP diagnosis (IQ-BTP) is an 11-item questionnaire aimed at detecting potential-BTP and classifying it into three likelihood classes: high, intermediate, and low. METHODS: A multicenter, prospective, and observational study was designed to validate the IQ-BTP. In three consecutive visits with each cancer patient, the demographic and clinical details of the patient, the Brief Pain Inventory (BPI) scores, IQ-BTP outcomes, and clinicians' autonomous BTcP diagnosis (gold standard) and the agreement of this diagnosis with IQ-BTP outcomes were recorded. The assessed domains for IQ-BTP validation were: Validity, including content and face validity, construct validity (hypothesis testing, and cross‐cultural validity\measurement invariance), and criterion validity; Reliability (internal consistency, reliability, and measurement error); Interpretability, and Responsiveness. RESULTS: Seven palliative and pain management facilities in Italy recruited 280 patients, yielding 753 evaluations. Using the IQ-BTP, the rate of potential-BTcP was 27.2%, of which its likely presence was high in 52.7% of patients, intermediate in 38.5, and low in 8.8%. The BPI item scores differed significantly between the two IQ-BTP classes (no-BTcP and potential-BTcP classes). The correlation of the latter class with BPI items was significant but low. The IQ-BTcP showed two principal components, accounting for 66.6% of the variance. Cronbach’s α was 0.71. The agreement rate between the gold standard and IQ-BTP outcomes was 82%. Cohen's [Formula: see text] was 0.535. The IQ-BTP showed sensitivity and specificity of 69 and 86%, respectively. CONCLUSIONS: The IQ-BTP extensive formal validation showed satisfactory psychometric and validity properties. Its content, face, construct, and criterion validities and its reliability, interpretability, and responsiveness were shown. Its use enabled potential-BTcP to be identified and differentiated into three likelihood classes with direct therapeutic and epidemiological implications. The latter may be confirmed in future studies. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40122-021-00274-9. Springer Healthcare 2021-06-06 2021-12 /pmc/articles/PMC8586321/ /pubmed/34091817 http://dx.doi.org/10.1007/s40122-021-00274-9 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Original Research
Samolsky Dekel, Boaz Gedaliahu
Gori, Alberto
Gunnellini, Marco
Gioia, Angela
Di Marco, Mariacristina
Casale, Giuseppe
Bevilacqua, Marzio
Bersani, Pietro
Melotti, Rita Maria
The Italian Questionnaire for Cancer Breakthrough Pain Diagnosis, a Multicenter Validation Study
title The Italian Questionnaire for Cancer Breakthrough Pain Diagnosis, a Multicenter Validation Study
title_full The Italian Questionnaire for Cancer Breakthrough Pain Diagnosis, a Multicenter Validation Study
title_fullStr The Italian Questionnaire for Cancer Breakthrough Pain Diagnosis, a Multicenter Validation Study
title_full_unstemmed The Italian Questionnaire for Cancer Breakthrough Pain Diagnosis, a Multicenter Validation Study
title_short The Italian Questionnaire for Cancer Breakthrough Pain Diagnosis, a Multicenter Validation Study
title_sort italian questionnaire for cancer breakthrough pain diagnosis, a multicenter validation study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8586321/
https://www.ncbi.nlm.nih.gov/pubmed/34091817
http://dx.doi.org/10.1007/s40122-021-00274-9
work_keys_str_mv AT samolskydekelboazgedaliahu theitalianquestionnaireforcancerbreakthroughpaindiagnosisamulticentervalidationstudy
AT gorialberto theitalianquestionnaireforcancerbreakthroughpaindiagnosisamulticentervalidationstudy
AT gunnellinimarco theitalianquestionnaireforcancerbreakthroughpaindiagnosisamulticentervalidationstudy
AT gioiaangela theitalianquestionnaireforcancerbreakthroughpaindiagnosisamulticentervalidationstudy
AT dimarcomariacristina theitalianquestionnaireforcancerbreakthroughpaindiagnosisamulticentervalidationstudy
AT casalegiuseppe theitalianquestionnaireforcancerbreakthroughpaindiagnosisamulticentervalidationstudy
AT bevilacquamarzio theitalianquestionnaireforcancerbreakthroughpaindiagnosisamulticentervalidationstudy
AT bersanipietro theitalianquestionnaireforcancerbreakthroughpaindiagnosisamulticentervalidationstudy
AT melottiritamaria theitalianquestionnaireforcancerbreakthroughpaindiagnosisamulticentervalidationstudy
AT samolskydekelboazgedaliahu italianquestionnaireforcancerbreakthroughpaindiagnosisamulticentervalidationstudy
AT gorialberto italianquestionnaireforcancerbreakthroughpaindiagnosisamulticentervalidationstudy
AT gunnellinimarco italianquestionnaireforcancerbreakthroughpaindiagnosisamulticentervalidationstudy
AT gioiaangela italianquestionnaireforcancerbreakthroughpaindiagnosisamulticentervalidationstudy
AT dimarcomariacristina italianquestionnaireforcancerbreakthroughpaindiagnosisamulticentervalidationstudy
AT casalegiuseppe italianquestionnaireforcancerbreakthroughpaindiagnosisamulticentervalidationstudy
AT bevilacquamarzio italianquestionnaireforcancerbreakthroughpaindiagnosisamulticentervalidationstudy
AT bersanipietro italianquestionnaireforcancerbreakthroughpaindiagnosisamulticentervalidationstudy
AT melottiritamaria italianquestionnaireforcancerbreakthroughpaindiagnosisamulticentervalidationstudy